Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients.
about
Workshop report on some new ideas about the treatment of systemic lupus erythematosus.First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104LJP 1082: a toleragen for Hughes syndrome.LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus.LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study.
P2860
Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients.
@en
type
label
Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients.
@en
prefLabel
Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients.
@en
P2093
P2860
P1433
P1476
Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients.
@en
P2093
G M Iverson
M D Linnik
M E Cronin
M H Weisman
P A McNeeley
P2860
P304
P356
10.1191/096120301701549642
P577
2001-01-01T00:00:00Z